

Supplementary Table S1 Cytokine secretion in response to vehicle (V), 10 nM estradiol (E₂) and 10 nM E₂ + 1 μM progesterone (E₂P₄) treatment in different study groups at day 14.

pg/10 ⁵ cells	Study group	V	E ₂	E ₂ P ₄
Fractalkine	Ctrl	26.0 ± 2.67	25.0 ± 2.67	32.0 ± 2.80
	dPCOS	21.5 ± 2.37	24.4 ± 2.68	30.1 ± 3.05
	ndPCOS	40.1 ± 6.02	27.0 ± 4.78	31.7 ± 6.92
GM-CSF	Ctrl	9.1 ± 3.09 ^{a,b,d}	2.1 ± 0.77	4.6 ± 1.50
	dPCOS	4.2 ± 0.95 ^{a,f}	1.2 ± 0.57 ^c	6.0 ± 1.47
	ndPCOS	13.3 ± 3.94 ^a	2.3 ± 0.26	9.5 ± 1.17
IL-6	Ctrl	76.2 ± 21.46 ^{b,d,e}	36.0 ± 9.87 ^e	20.2 ± 4.21 ^e
	dPCOS	33.3 ± 7.57 ^f	19.0 ± 4.26 ^f	18.5 ± 6.03 ^f
	ndPCOS	204 ± 41.4 ^{a,b}	95 ± 21.6	89 ± 20.6
IL-8	Ctrl	713 ± 83.5 ^b	207 ± 38.0	1376 ± 346.8 ^e
	dPCOS	311 ± 92.1	117 ± 29.6 ^c	954 ± 485.2 ^f
	ndPCOS	1244 ± 285.1 ^b	437 ± 74.9 ^c	3248 ± 1574.4
IL-11	Ctrl	8.2 ± 4.34	1.6 ± 1.14	0.5 ± 0.29
	dPCOS	1.9 ± 1.11	0.5 ± 0.41	0.8 ± 0.72
	ndPCOS	3.49 ± 1.20	1.57 ± 0.76	0.99 ± 0.67
MCP-1 (CCL2)	Ctrl	1742 ± 285.2	1451 ± 395.4	990 ± 423.5
	dPCOS	1204 ± 204.4 ^f	668 ± 178.7	595 ± 127.6
	ndPCOS	2738 ± 732.3 ^{a,b}	1442 ± 519.9	1121 ± 426.8
MCP-3 (CCL7)	Ctrl	31.0 ± 12.06	16.2 ± 8.48	12.4 ± 6.89
	dPCOS	15.5 ± 5.65	6.9 ± 2.24	7.5 ± 2.79
	ndPCOS	23.5 ± 1.92	11.4 ± 1.54	11.5 ± 2.11
RANTES (CCL5)	Ctrl	0.63 ± 0.08 ^e	0.55 ± 0.09	1.58 ± 0.27 ^e
	dPCOS	0.85 ± 0.25 ^{b,f}	0.87 ± 0.19 ^c	2.22 ± 0.48
	ndPCOS	3.6 ± 1.09 ^a	1.7 ± 0.56 ^c	3.3 ± 0.75

DCtrl, eSF from controls; dPCOS eSF from women with PCOS (8/12), that exhibit decidualization; ndPCOS, eSF from women with PCOS (4/12), that did not.

Significances in *t*-test.

^aV versus E₂.

^bV versus E₂P₄.

^cE₂ versus E₂P₄.

^dCtrl versus Dpcos.

^eCtrl versus ndPCOS.

^fdPCOS versus ndPCOS.